Eli Lilly and Company (NYSE:LLY) Q2 2024 Results Conference Call August 8, 2024 11:30 AM ET
Company Participants
Joe Fletcher - Senior Vice President-Investor Relations
Dave Ricks - Chief Executive Officer
Gordon Brooks - Group VP, Controller & Corporate Strategy and Interim CFO
Dan Skovronsky - Chief Scientific Officer and President-Lilly Immunology
Patrik Jonsson - President-Lilly Diabetes and Obesity and Lilly USA
Ilya Yuffa - Executive Vice President
Conference Call Participants
Seamus Fernandez - Guggenheim
Terence Flynn - Morgan Stanley
Chris Schott - JPMorgan
Tim Anderson - Wolfe Research
Umer Raffat - Evercore
Mohit Bansal - Wells Fargo
Alex Hammond - Bank of America
Evan Seigerman - BMO Capital Markets
David Risinger - Leerink Partners
Kerry Holford - Berenberg
Chris Shibutani - Goldman Sachs
Akash Tewari - Jefferies
Trung Huynh - UBS
Steve Scala - TD Cowen
Louise Chen - Cantor
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2024 Earnings Call. [Operator Instructions]. I would now like to turn the conference over to your host, Joe Fletcher, Senior Vice President of Investor Relations. Please go ahead.
Joe Fletcher
Thanks, Paul. Good morning, everyone. Thanks for joining us for Eli Lilly and Company's Q2 2024 earnings call. I'm Joe Fletcher, Senior Vice President of Investor Relations. And joining me on today's call are Dave Ricks, Lilly's Chairman and CEO; and Dr. Dan Skovronsky, Chief Scientific Officer and President of Lilly Immunology; Gordon Brooks, Interim Financial -- Chief Financial Officer; Anne White, President of Lilly Neuroscience; Ilya Yuffa, President of Lilly International; Jake Van Naarden, President of Lilly Oncology; and Patrik Jonsson, President of Lilly Cardiometabolic Health and Lilly USA. And we're also joined by Makela Irons, Mike Springate, Lauren Zurke of the IR team.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to several factors, including those listed on Slide 4. Additional information concerning factors that could cause actual results to differ materially is contained in our latest Form 10-K and subsequent filings with the SEC.
The information we provide about our products and pipeline is for the benefit of the investment community. It's not intended to be promotional and is not sufficient for prescribing decisions. As we transition to our prepared remarks, please note that our commentary will focus on non-GAAP financial measures.
Now I'll turn the call over to Dave.